Collaboration and Company Update

Hemogenyx signs a Lithuanian LOI, but all clinical and financial milestones remain unproven.

What the company is saying

Hemogenyx Pharmaceuticals plc announces the signing of a Letter of Intent with the National Cancer Centre at Vilnius University Hospital Santaros Klinikos for a scientific and clinical collaboration targeting FLT3-positive AML and MDS. The company frames this as a two-pronged initiative: translational research and in-hospital manufacturing plus clinical use of its FLT3 CAR-T therapy, HG-CT-1. The narrative emphasizes retained intellectual property, potential for parallel data collection in Lithuania and the US, and the company’s ongoing Phase 1 trials in both adults and children. Language throughout stresses intent, future collaboration, and scientific leadership, but avoids quantifying progress or specifying commercial terms. The tone is optimistic and forward-leaning, but concrete achievements are limited to the LOI signing and trial initiation.

What the data suggests

The only realised data points are the signing of the LOI, the ongoing adult Phase 1 trial of HG-CT-1, and the identification and screening of the first pediatric patient. No patient enrollment numbers, treatment outcomes, or financial metrics are disclosed. There is no evidence of patient dosing, regulatory clearance in Lithuania, or any clinical data generated from the new collaboration. The announcement lacks figures on R&D spend, compensation arrangements, or projected revenues. All references to manufacturing, technology transfer, and data collection are aspirational. The absence of concrete numbers or operational milestones means the financial trajectory and operational progress cannot be independently assessed.

Analysis

The announcement is positive in tone, highlighting a new Letter of Intent for a scientific and clinical collaboration in Lithuania and providing updates on ongoing clinical trials. However, the majority of the claims are forward-looking or aspirational, such as intentions to establish in-hospital manufacturing, future patient treatment, and potential data collection, with no concrete timelines or evidence of execution. Only the signing of the LOI and the ongoing status of Phase 1 trials are realised facts; all other benefits are contingent on future actions and regulatory approvals. There is no disclosure of financial metrics, patient enrollment numbers, or operational milestones achieved, and the capital outlay required for technology transfer and manufacturing setup is referenced but not quantified or matched with near-term returns. The language inflates the signal by implying imminent progress and commercial potential, but the actual evidence supports only early-stage collaboration and trial activity. The gap between narrative and evidence is significant, as no measurable clinical or financial outcomes are reported.

Risk flags

• ●Execution risk is high because the collaboration is at the LOI stage, not a binding agreement, and requires substantial preparatory work before any patient treatment can begin. The absence of a definitive agreement means terms, timelines, and deliverables remain uncertain.
• ●Operational risk is significant as there is no evidence of regulatory approval, established manufacturing, or patient dosing in Lithuania. The process involves complex technology transfer, compliance with Lithuanian and EU law, and coordination across institutions.
• ●Financial risk is elevated due to the lack of disclosed compensation terms, revenue projections, or cost estimates for the collaboration. The company references resource prioritization and compensation negotiations, but provides no numbers or funding commitments.
• ●Disclosure risk is present because the announcement omits key quantitative details such as patient numbers, trial progress metrics, or financial data, limiting transparency and making it difficult for investors to gauge actual progress.

Bottom line

This announcement signals Hemogenyx’s intent to expand its clinical and research footprint into Lithuania, but all operational and financial outcomes are speculative at this stage. The only realised milestones are the LOI signing and ongoing Phase 1 trials, with no evidence of patient treatment, regulatory clearance, or revenue generation from the new collaboration. The company’s narrative is optimistic but unsupported by concrete data or timelines. For investors, this update is not actionable until definitive agreements are signed, patient treatments begin, or measurable clinical and financial results are disclosed. The most important takeaway is that the collaboration is early-stage and carries substantial execution, operational, and financial risks.

Announcement summary

(LSE:HEMO) Hemogenyx Pharmaceuticals plc announced that it has signed a Letter of Intent with the National Cancer Centre at Vilnius University Hospital Santaros Klinikos to establish a scientific and clinical collaboration in FLT3-positive acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The collaboration comprises two workstreams: a translational research program characterizing FLT3 expression and biology across AML/MDS genetic subtypes, and in-hospital (point-of-care) manufacturing and clinical use of Hemogenyx's FLT3-directed CAR-T cell therapy (HG-CT-1) to eligible patients. Patient treatment is intended to be carried out under the hospital exemption rules and other applicable pathways in force in the Republic of Lithuania, consistent with Lithuanian and EU law governing advanced therapy medicinal products. Hemogenyx retains full ownership of all intellectual property, know-how, data and regulatory rights relating to the Therapy and its FLT3 CAR-T technology. The collaboration may enable Hemogenyx to receive clinical data from the treatment of R/R AML patients in Lithuania in parallel with the Company's ongoing clinical trials in the United States. Hemogenyx continues its Phase 1 clinical trial of HG-CT-1 in adult patients with R/R AML, and has initiated a pediatric Phase 1 clinical trial of HG-CT-1, with the first pediatric patient identified and undergoing screening. The Company continues to develop its CBR platform and CDX bispecific antibody for the treatment of R/R AML, but development is proceeding at a measured pace while prioritizing HG-CT-1.

Disagree with this article?